Cited by Crossref (7)

  1. Yujin Shin, Ji Hye Moon, Ho Jun Chin, Ele Ferrannini, Soo Lim. Glycemic Efficacy and Metabolic Consequences of an Empagliflozin Add-on versus Conventional Dose-Increasing Strategy in Patients with Type 2 Diabetes Inadequately Controlled by Metformin and Sulfonylurea. Endocrinol Metab 2020;35:329
    https://doi.org/10.3803/EnM.2020.35.2.329
  2. Awadhesh Kumar Singh, Ambika G. Unnikrishnan, Abdul H. Zargar, Ajay Kumar, Ashok K. Das, Banshi Saboo, Binayak Sinha, Kalyan Kumar Gangopadhyay, Pradeep G. Talwalkar, Samit Ghosal, Sanjay Kalra, Shashank Joshi, Surendra Kumar Sharma, Usha Sriram, Viswanathan Mohan. Evidence-Based Consensus on Positioning of SGLT2i in Type 2 Diabetes Mellitus in Indians. Diabetes Ther 2019;10:393
    https://doi.org/10.1007/s13300-019-0562-1
  3. Ayaka Domon, Kentaro Katayama, Touko Sato, Yuki Tochigi, Hiroyuki Tazaki, Hiroetsu Suzuki, Michael Bader. Empagliflozin ameliorates symptoms of diabetes and renal tubular dysfunction in a rat model of diabetes with enlarged kidney (DEK). PLoS ONE 2021;16:e0251135
    https://doi.org/10.1371/journal.pone.0251135
  4. Hyo Jin Maeng, Gha Young Lee, Jae Hyun Bae, Soo Lim. Effect of Fibroblast Growth Factor 21 on the Development of Atheromatous Plaque and Lipid Metabolic Profiles in an Atherosclerosis-Prone Mouse Model. IJMS 2020;21:6836
    https://doi.org/10.3390/ijms21186836
  5. Ji A Seo. Sodium-Glucose Co-transporter 2 Inhibitor: The Magic Bullet for Obesity in Diabetes?. JOMES 2018;27:1
    https://doi.org/10.7570/jomes.2018.27.1.1
  6. Sook Jung Lee, Kook Hyung Lee, Hyun Geong Oh, Hye Ji Seo, Soo Jin Jeong, Chong Hwa Kim. Effect of Sodium-Glucose Cotransporter-2 Inhibitors versus Dipeptidyl Peptidase 4 Inhibitors on Cardiovascular Function in Patients with Type 2 Diabetes Mellitus and Coronary Artery Disease. JOMES 2019;28:254
    https://doi.org/10.7570/jomes.2019.28.4.254
  7. Angelo Avogaro, Saula Vigili de Kreutzenberg, Mario Luca Morieri, Gian Paolo Fadini, Stefano Del Prato. Glucose-lowering drugs with cardiovascular benefits as modifiers of critical elements of the human life history. The Lancet Diabetes & Endocrinology 2022;10:882
    https://doi.org/10.1016/S2213-8587(22)00247-9